Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.” ...

The CEOs say the merger could be transformative for robotic laser technology in the cataract surgery industry.

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

manufactured by Alcon Laboratories, following a report of fungal material found in a sealed vial. No illnesses have been reported, but fungal contamination can pose vision-threatening risks and ...

Within Vision Care, Alcon is registering solid growth, banking on strong sales of its contact lenses and ocular health products. In contact lenses, Alcon, with its strategic investments ...

Vision care made up 43% of fiscal 2023 total ... Thanks to these high-performing products and its brand power, Alcon has been able to achieve over 80% and 55% of the domestic and global presbyopia ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader ... that they have glaucoma until the disease has progressed to vision loss. Due to its progressive nature, early intervention ...

This milestone highlights Alcon's commitment to enhancing vision care, offering patients a premium presbyopia-correcting solution. The introduction of Clareon Vivity IOL marks a significant ...